CD274 and neoplasm: The ATEZOLACC trial is a multicentre randomised phase II trial prospectively testing the addition of the programmed death ligand 1 (PD-L1) inhibitor atezolizumab to enhance tumour immunogenicity in patients undergoing CCRT with cisplatin.